SERINE
Non-alcoholic Fatty Liver Disease (NAFLD)
ScandiBio Therapeutics ABSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Non-alcoholic Fatty Liver Disease (NAFLD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docosahexaenoic Acid Hawler Medical University | Phase 3 | BB |
lcq908 Novartis Pharmaceuticals | Phase 2 | B |
SORBITOL ScandiBio Therapeutics AB | Phase 2 | B |
Nicotinamide Ribonucleoside ScandiBio Therapeutics AB | Phase 2 | B |
Cotadutide MedImmune LLC | Phase 2 | B |
View all 11 →
Same molecule, other indications
SERINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →